Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum β-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study

Mt, Albertini; Benoît, C.; Berardi, Luigia; Berrouane, Y.; Boisivon, A; Cahen, P; Cattöen, C.; Costa, Yannick; P, Darchis; Deliere, Elisabeth; Demontrond, D.; F, Eb; Golliot, Franck; Grise, G; Harel, Asaff; Jl, Koeck; Mp, Lepennec; Malbrunot, C.; Marcollin, M; Maugat, S.; Nouvellon, M.; Pangon, B.; Ricouart, S; Roussel-Delvallez, M.; Vachée, Anne; Carbonne, A.; Marty, L; Jarlier,

doi:10.1053/jhin.2002.1286

Cited by 67 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, there has been a slight fall in the number of K. pneumoniae producing ESBL in Western Europe, likely due to enhanced infection control practices and antimicrobial stewardship [29]. However, this is not true for Eastern Europe, where numbers of resistant isolates appear to rising [30].…”

Section: Epidemiologymentioning

confidence: 99%

ESBLs: A Clear and Present Danger?

Dhillon

Clark

2012

Critical Care Research and Practice

144

141

View full text Add to dashboard Cite

Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme-producing organisms are associated with a higher morbidity and mortality and greater fiscal burden. Coupled with increasing prevalence rates worldwide and an ever diminishing supply in the antibiotic armamentarium, these enzymes represent a clear and present danger to public health. This article aims to give an overview of the current situation regarding ESBLs, with a focus on the epidemiology and management of such infections.

show abstract

Section: Epidemiologymentioning

confidence: 99%

ESBLs: A Clear and Present Danger?

Dhillon

Clark

2012

Critical Care Research and Practice

144

141

View full text Add to dashboard Cite

show abstract

“…Methicillin resistant Staphylococcus aureus (MRSA) strains emerged soon after the introduction of methicillin into clinical practice. MRSA is one of the major pathogen associated with serious nosocomial infection because this strain shows multiple drug resistance which limits treatment possibilities 1 . Numerous clinical studies have indicated, based on mortality rates, that MRSA strains are more virulent than methicillin-susceptible S. aureus (MSSA) strains 2 .…”

mentioning

confidence: 99%

Colorimetric method for rapid detection of Oxacillin resistance in Staphylococcus aureus and its comparison with PCR for mec A gene

Ghanwate

Thakare

Bhise

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Rapid and accurate detection of Methicillin Resistant Staphylococcus aureus (MRSA) is an important role of clinical microbiology laboratories to avoid treatment failure. The detection of MRSA is basedon phenotypic assays which require at least 24 h to perform. Detection of the mecA gene or of PBP 2a is the "gold standard", but not always available. The aim of this study was to evaluate a rapid method for detection of MRSA by using 3 (4, 5 dimethyl thiazole -2-yl) -2, 5 diphenyl tetrazolium bromide (MTT). Total 126 isolates of MRSA were collected from tertiary healthcare center and were confirmed by oxacillin screening agar test as per CLSI guidelines. Amplification of mecA gene was performed by using PCR. MTT assay was carried out for all the isolates in 96 well Microtitre plate and compared with standard methods of CLSI. Out of 126 isolates, 98 were found to be mecA positive. MTT method was found to be 98.98% sensitive and 96.43% specific. The MTT based colorimetric method is rapid and simple test for screening of oxacillin resistance in Staphylococcus aureus. It significantly shortens the time to just 7 h required to obtained a drug susceptibility test and could be useful to screen MRSA.Methicillin resistant Staphylococcus aureus (MRSA) strains emerged soon after the introduction of methicillin into clinical practice. MRSA is one of the major pathogen associated with serious nosocomial infection because this strain shows multiple drug resistance which limits treatment possibilities 1 . Numerous clinical studies have indicated, based on mortality rates, that MRSA strains are more virulent than methicillin-susceptible S. aureus (MSSA) strains 2 . The proportion of patients whose death is attributable to MRSA is significantly higher than that for MSSA 3 . Resistance to oxacillin is mostly mediated by the mecA gene, which codes for the production of a supplemental penicillin-binding protein, PBP2a or 2′, which is expressed either homogeneously or heterogeneously 4,5 . Expression of resistance in some MRSA strains is also regulated by homologues of the regulatory genes for blaZ that encodes for β -lactamase. These genes, mecI and mecR1, regulate the mecA response to β -lactam antibiotics in a fashion similar to that of the regulation of blaZ by the genes blaR1 and blaI upon exposure to penicillin 6 . Rosato et al. 7 have found that either mecI or blaI must be functional in all MRSA. An additional series of genes, the fem genes (factor essential for resistance to methicillin resistance), play a role in cross-linking peptidoglycan strands and also contributes to the heterogeneity of expression of methicillin resistance 8 . The typical heterogeneity seen in the expression of resistance to methicillin and in levels of resistance depends on the concerted action of chromosomally encoded genes, including fem and aux that are also present in the genome of susceptible staphylococci. Early detection of drug resistance is one of the essential steps in the management of MRSA infections and the effectiveness of a standard Anti-...

show abstract

“…Whereas in Spain, only 1.5% among 1962 invasive E. coli isolates in 2001 were found to produce ESβL [60]. In contrary, France had 11.4% K. pneumoniae and 47.7% E. aerogenes isolates were seen which produced ESβL in a surveillance covering many medical centres during 1996 to 2000 [61]. Northern European countries still have the lowest prevalence of ESβLproducing Enterobacteriaceae ranging from <1% in the Netherlands to 3% in Sweden.…”

Section: Epidemiology Of Esβlsmentioning

confidence: 96%

“…It has been observed that ESβL allele may be restricted to certain country or a certain geographical region, like blaTEM-10 that has been detected in the United States in several outbreaks for many years before the detection of this allele was found in Europe [62]. Another example demonstrated by blaTEM-3 which has not been detected in the United States but is been frequently observed in France [63].…”

Section: Epidemiology Of Esβlsmentioning

confidence: 99%

An Overview of Extended Spectrum Beta Lactamases and Metallo Beta Lactamases

Nagshetty¹,

Shilpa²,

Patil³

et al. 2021

AiM

View full text Add to dashboard Cite

Antibiotic resistant β-lactamases are diverse and complex enzymes produced by most of the Gram-negative bacteria that are mediated by number of plasmids. The impact of these enzymes has posed a major threat to the health sectors and has challenged the available treatment options for both community and hospital acquired infections. These include the uncomplicated most severe life-threatening infections. Moreover, with resistance to the cephalosporin drugs these Multidrug Resistance strains exhibit co-resistance patterns with different class of antibiotics which is a cause of concern that leads to narrow the limited treatment options. It is alarming situation since there is a steep rise in MDR-Beta lactamase pathogens mainly in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Currently, the clinical detection of Extended Spectrum of β-Lactamases (ESβL) and MβL producing pathogens are carried out by antibiotic sensitivity test on the guidelines of Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) since, the other methods being too expensive. The choice of antimicrobial treatment for infections should rely on the clinical data and the tests (AST) in asymptomatic and mild cases. However, this does not imply for critical infections. The last resorts of treatment for ESβL pathogens are carbapenem and nevertheless, resistances have also been reported for the same. With increasing resistance rate to the antibiotics, it is very essential to follow the guidelines for detection, implementation of antibiotic rotation to reduce these pathogens, followed by the efficient infection control practices and strategies to avoid such outbreaks.

show abstract

Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum β-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study

Cited by 67 publications

References 29 publications

ESBLs: A Clear and Present Danger?

ESBLs: A Clear and Present Danger?

Colorimetric method for rapid detection of Oxacillin resistance in Staphylococcus aureus and its comparison with PCR for mec A gene

An Overview of Extended Spectrum Beta Lactamases and Metallo Beta Lactamases

Contact Info

Product

Resources

About